# Calithera Biosciences, Inc clinical trials: 29 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 29 trials with Calithera Biosciences, Inc as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Calithera Biosciences, Inc: 29 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/calithera-biosciences-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 29
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 29, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 8, 2022 | NCT05319028 | Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Calithera Biosciences, Inc | Phase 2 | Terminated | Non-GCB/ABC Diffuse Large B-Cell Lymphoma, With and Without MyD88 and/or CD79B Mutations | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05319028) |
| January 7, 2021 | NCT04698681 | NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial | Calithera Biosciences, Inc | Observational | Terminated | Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04698681) |
| October 29, 2020 | NCT04607512 | Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects | Calithera Biosciences, Inc | Phase 1 | Completed | Cardiac Safety | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04607512) |
| September 7, 2020 | NCT04540965 | Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects | Calithera Biosciences, Inc | Phase 1 | Completed | Drug Interaction | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04540965) |
| February 21, 2020 | NCT04279769 | Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis | Calithera Biosciences, Inc | Phase 1 | Completed | Cystic Fibrosis | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04279769) |
| February 11, 2020 | NCT04265534 | KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC | Calithera Biosciences, Inc | Phase 2 | Terminated | Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04265534) |
| May 29, 2019 | NCT03965845 | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors | Calithera Biosciences, Inc | Phase 1/2 | Completed | Solid Tumors, NSCLC, CRC, KRAS Gene Mutation | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03965845) |
| March 14, 2019 | NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | Calithera Biosciences, Inc | Phase 1/2 | Terminated | Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer, CRC, RCC, ccRCC | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03875313) |
| December 11, 2018 | NCT03772288 | A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) | Calithera Biosciences, Inc | Phase 1 | Withdrawn | Lymphoma, Non-Hodgkin | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03772288) |
| February 9, 2018 | NCT03428217 | CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma | Calithera Biosciences, Inc | Phase 2 | Completed | Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | 444 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03428217) |
| December 12, 2017 | NCT03370302 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With... | Calithera Biosciences, Inc | Phase 1 | Terminated | Advanced Nonhematological Neoplasms | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03370302) |
| December 2, 2017 | NCT03359733 | A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor | Calithera Biosciences, Inc | Phase 1 | Withdrawn | Lymphoma, Malignant, Advanced Solid Neoplasms | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03359733) |
| November 30, 2017 | NCT03357627 | A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma | Calithera Biosciences, Inc | Phase 1 | Completed | Lymphoma, Non-Hodgkin, Lymphoma, Large B-cell, Diffuse, Lymphoma, Follicular | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03357627) |
| November 9, 2017 | NCT03338881 | A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered \[14 C\]-TAK-659 in Participants With Advanced... | Calithera Biosciences, Inc | Phase 1 | Withdrawn | Advanced Solid Neoplasms, Lymphoma Neoplasms | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03338881) |
| August 3, 2017 | NCT03238651 | A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) | Calithera Biosciences, Inc | Phase 1 | Terminated | Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Marginal Zone | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03238651) |
| May 23, 2017 | NCT03163667 | CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) | Calithera Biosciences, Inc | Phase 2 | Completed | Clear Cell Renal Cell Carcinoma | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03163667) |
| April 21, 2017 | NCT03123393 | TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Calithera Biosciences, Inc | Phase 2 | Terminated | Diffuse Large B-cell Lymphoma | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03123393) |
| February 20, 2017 | NCT03057600 | Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative... | Calithera Biosciences, Inc | Phase 2 | Completed | Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03057600) |
| October 25, 2016 | NCT02944435 | A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults | Calithera Biosciences, Inc | Phase 1 | Completed | Healthy Volunteers | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02944435) |
| July 15, 2016 | NCT02834247 | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | Calithera Biosciences, Inc | Phase 1 | Terminated | Triple-Negative Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Carcinoma, Squamous Cell, Advanced... | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02834247) |
| May 13, 2016 | NCT02771626 | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung... | Calithera Biosciences, Inc | Phase 1/2 | Terminated | Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma, Non-small Cell Lung Cancer (NSCLC) | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02771626) |
| April 29, 2016 | NCT02756364 | Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy | Calithera Biosciences, Inc | Phase 2 | Completed | Breast Neoplasms | 141 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02756364) |
| December 23, 2014 | NCT02323113 | Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML) | Calithera Biosciences, Inc | Phase 1/2 | Terminated | Acute Myelogenous Leukemia | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02323113) |
| July 22, 2014 | NCT02197572 | Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors | Calithera Biosciences, Inc | Phase 1 | Completed | Advanced Solid Tumors | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02197572) |
| February 26, 2014 | NCT02071927 | Study of the Glutaminase Inhibitor CB-839 in Leukemia | Calithera Biosciences, Inc | Phase 1 | Completed | Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02071927) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 16 |
| Phase 1/2 | 4 |
| Phase 2 | 8 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 16 |
| Terminated | 10 |
| Withdrawn | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Carcinoma, Renal Cell | 5 |
| Lymphoma, Non-Hodgkin | 4 |
| Triple Negative Breast Neoplasms | 4 |
| Lymphoma | 2 |
| Breast Neoplasms | 2 |
| Lymphoma, Large B-Cell, Diffuse | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Colorectal Neoplasms | 1 |
| Mesothelioma | 1 |
| Lymphoma, Follicular | 1 |
| Cystic Fibrosis | 1 |
| Kidney Neoplasms | 1 |
| Multiple Myeloma | 1 |
| Waldenstrom Macroglobulinemia | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Recurrence | 1 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 |
| Leukemia | 1 |
| Melanoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Tiling contractors in the United States](https://specstream.ai/data/businesses/tiling-contractors/united-states)
- [Metal fabricators in the United States](https://specstream.ai/data/businesses/metal-fabricators/united-states)
- [Egyptian restaurants in the United States](https://specstream.ai/data/businesses/egyptian-restaurants/united-states)
- [Aircraft manufacturers in the United States](https://specstream.ai/data/businesses/aircraft-manufacturers/united-states)
- [Playground equipment suppliers in the United States](https://specstream.ai/data/businesses/playground-equipment-suppliers/united-states)
- [German restaurants in the United States](https://specstream.ai/data/businesses/german-restaurants/united-states)
